| Insurance Industry | Financials Sector | Connor Yuen CEO | OTCQB Exchange | CA2684692023 ISIN |
| CA Country | - Employees | - Last Dividend | 11 Jul 2022 Last Split | - IPO Date |
EGF Theramed Health Corp. is a pioneering company dedicated to the development of psychedelic drugs for the treatment of various mental health conditions. This innovative firm is engaged in researching and producing therapies for serious health issues such as treatment-resistant depression, anxiety, post-traumatic stress disorder (PTSD), and general depression. Alongside its focus on psychedelic medicine, EGF Theramed also offers a range of natural health and wellness products. The company is strategically headquartered in Vancouver, Canada, positioning itself within a supportive environment for biotechnological and health sciences research and development.
At the core of EGF Theramed Health Corp.'s product lineup are its psychedelic drug therapies, designed to address hard-to-treat mental health conditions. These conditions include treatment-resistant depression, anxiety, PTSD, and depression. By focusing on these areas, EGF Theramed aims to provide innovative, effective treatments for patients who have not found relief through traditional methods.
In addition to its work in psychedelic drug development, EGF Theramed Health Corp. offers a variety of natural health and wellness products. These products are aimed at improving overall health, wellness, and quality of life. By integrating natural products with cutting-edge psychedelic drug therapies, EGF Theramed provides a holistic approach to mental health and wellness, catering to a wide range of needs and preferences among its customer base.